Currently, Plus Therapeutics Inc [PSTV] is trading at $1.44, up 311.43%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PSTV shares have gain 113.33% over the last week, with a monthly amount glided 15.20%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Plus Therapeutics Inc [NASDAQ: PSTV] stock has seen the most recent analyst activity on January 25, 2021, when Ladenburg Thalmann initiated its Buy rating and assigned the stock a price target of $8. Previously, Maxim Group started tracking the stock with Buy rating on October 16, 2020, and set its price target to $6.
This stock has fluctuated between a low of $0.24 and a high of $2.67 over the last 52 weeks. Plus Therapeutics Inc [NASDAQ: PSTV] shares were valued at $1.44 at the most recent close of the market.
Analyzing the PSTV fundamentals
Trailing Twelve Months sales for Plus Therapeutics Inc [NASDAQ:PSTV] were 5.72M which represents 17.42% growth. Gross Profit Margin for this corporation currently stands at 0.26% with Operating Profit Margin at -3.43%, Pretax Profit Margin comes in at -3.02%, and Net Profit Margin reading is -3.02%. To continue investigating profitability, this company’s Return on Assets is posted at -1.85, Equity is 2.71 and Total Capital is 2.85. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.66.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7600 points at the first support level, and at 0.0800 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.8300, and for the 2nd resistance point, it is at 2.2200.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Plus Therapeutics Inc [NASDAQ:PSTV] is 0.44. Also, the Quick Ratio is 0.44, while the Cash Ratio stands at 0.1. Considering the valuation of this stock, the price to sales ratio is 1.48.
Transactions by insiders
Recent insider trading involved Hawkins Richard J, Director, that happened on Sep 13 ’24 when 4000.0 shares were purchased. Director, Hawkins Richard J completed a deal on Sep 12 ’24 to buy 6285.0 shares. Meanwhile, Director Petersen Greg bought 12500.0 shares on Sep 11 ’24.
